Charles River Laboratories
251 Ballardvale Street
Wilmington
Massachusetts
01887
United States
Tel: 877-274-8371
Website: http://www.criver.com/
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
444 articles with Charles River Laboratories
-
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
3/13/2023
Charles River Laboratories International, Inc. (NYSE: CRL) today launched Apollo™ , an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study milestones, documents, cost estimates, and program planning tools to save time and enhance the client experience.
-
Charles River Laboratories to Present at Barclays Global Healthcare Conference - March 13, 2023
3/13/2023
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th , at 10:15 a.m. ET.
-
Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing
3/9/2023
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.
-
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
2/22/2023
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2022 and provide guidance for 2023.
-
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
2/16/2023
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines access to Logica™
-
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
2/15/2023
Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
-
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
2/13/2023
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics.
-
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
2/9/2023
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22nd, before the market opens.
-
Charles River Laboratories Acquires SAMDI Tech
1/30/2023
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc , a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research.
-
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
1/18/2023
Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. today announced a viral vector contract development and manufacturing organization (CDMO) partnership.
-
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
1/16/2023
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrime TM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials.
-
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
1/12/2023
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience.
-
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
12/6/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board of Directors. Dr. Thompson previously served as a member of Charles River’s Board of Directors from 2013 through 2018.
-
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
12/1/2022
Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe ® Nexus 200™ , expanding its robust endotoxin testing portfolio.
-
Charles River Laboratories to Present at November Investor Conferences
11/14/2022
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences.
-
Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022
11/10/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 23 scientific posters, both independently and collaboratively with clients, at Neuroscience 2022, the annual meeting of the Society for Neuroscience (SfN).
-
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients
11/7/2022
Charles River Laboratories International, Inc. announced the expansion of its cell therapy contract development and manufacturing facility in Memphis, Tenn.
-
Charles River Laboratories Announces Third-Quarter 2022 Results
11/2/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2022.
-
Charles River Launches HemaCare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research
10/19/2022
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of a new digital donor experience to enhance access to its donor centers in four distinct US geographic markets.
-
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
10/18/2022
Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced a comprehensive manufacturing collaboration utilizing Charles River's extensive contract development and manufacturing services in both plasmid DNA and viral vectors.